跳转至内容
Merck

A1276

Sigma-Aldrich

Amastatin hydrochloride hydrate

powder, ≥97% (HPLC)

别名:

(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl-Val-Val-Asp hydrochloride hydrate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H38N4O8 · HCl · xH2O
分子量:
511.01 (anhydrous basis)
Beilstein:
8888370
MDL號碼:
分類程式碼代碼:
12352202
PubChem物質ID:
NACRES:
NA.77

product name

Amastatin hydrochloride hydrate, ≥97% (HPLC)

生物源

synthetic (organic)

品質等級

化驗

≥97% (HPLC)

形狀

powder

mp

202-205 °C

溶解度

methanol: 1 mM (Stock solution stable for 1 month at −20 °C. Working solution stable for 1 day.)

抗生素活性譜

neoplastics

作用方式

enzyme | inhibits

儲存溫度

−20°C

SMILES 字串

Cl[H].[H]O[H].CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O

InChI

1S/C21H38N4O8.ClH.H2O/c1-9(2)7-12(22)17(28)20(31)25-16(11(5)6)19(30)24-15(10(3)4)18(29)23-13(21(32)33)8-14(26)27;;/h9-13,15-17,28H,7-8,22H2,1-6H3,(H,23,29)(H,24,30)(H,25,31)(H,26,27)(H,32,33);1H;1H2/t12-,13+,15+,16+,17+;;/m1../s1

InChI 密鑰

WBYDQJQQTMJMQH-AFROIDPFSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

Chemical structure: peptide

生化/生理作用

It inhibits cytosolic leucine aminopeptidase (EC.3.4.11.1), microsomal aminopeptidase M (EC.3.4.11.2) and bacterial leucine aminopeptidase (EC.3.4.11.10). It is less effective against aminopeptidase A (EC 3.4.11.7), the enzyme that converts angiotensin II to angiotensin III. Potentiates the CNS effects of vasopressin and oxytocin in vivo.

Effective concentration: 1-10 μM.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

Beynon, R.J. and Bond, J.S.
Proteolytic Enzymes: A Practical Approach, 247-247 (1989)
Zollner, H.
Handbook of Enzyme Inhibitors, 2nd Ed., 547-547 (1993)
Yu Wang et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(3), e21419-e21419 (2021-02-11)
In the early phase of the Coronavirus disease 2019 (COVID-19) pandemic, it was postulated that the renin-angiotensin-system inhibitors (RASi) increase the infection risk. This was primarily based on numerous reports, which stated that the RASi could increase the organ Angiotensin-converting

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门